Last reviewed · How we verify

NCT06914180

Esketamine Combined With PRF for Trigeminal Postherpetic Neuralgia

Not yet recruiting NA Last updated 9 April 2025
What this trial tests

NA trial testing esketamine group in Postherpetic; Neuralgia, Trigeminal (Etiology) in 174 participants. Not yet recruiting.

Timeline
1 April 2025
Primary endpoint
1 April 2026
1 July 2026

Quick facts

Lead sponsorBeijing Tiantan Hospital
PhaseNA
StatusNot yet recruiting
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment174
Start date1 April 2025
Primary completion1 April 2026
Estimated completion1 July 2026
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Beijing Tiantan Hospital

Who can join

18 and older, any sex, with Postherpetic; Neuralgia, Trigeminal (Etiology). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This trial's primary objective is to compare the analgesic efficacy of esketamine in combination with pulsed radiofrequency (PRF) against that of PRF monotherapy in patients with trigeminal postherpetic neuralgia (TPHN).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of esketamine group

Trials testing the same drug.

Other Beijing Tiantan Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06914180.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing